Neogen Corporation Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Neogen Corporation (NEOG) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 43.40% for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-07-30
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2020-08-31 was 29.40%, a 8.89% increase year-over-year.
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2019-08-31 was 27.00%.
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2013-08-31 was 33.10%.
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2026 was 43.40%, a 13.91% increase from fiscal 2025.
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 38.10%, a 2.14% increase from fiscal 2024.
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 37.30%, a 9.71% increase from fiscal 2023.
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 34.00%, a 3.66% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2026-05-31 | 43.40% 10-K · filed 2026-07-30 | ||||
| 2025-05-31 | 38.10% 10-K · filed 2026-07-30 | ||||
| 2024-05-31 | 37.30% 10-K · filed 2026-07-30 | ||||
| 2023-05-31 | 34.00% 10-K · filed 2025-07-30 | ||||
| 2022-05-31 | 32.80% 10-K · filed 2024-07-30 | ||||
| 2022-02-28 | 32.80% 10-Q · filed 2022-04-01 | ||||
| 2021-05-31 | 31.30% 10-K · filed 2023-08-15 | ||||
| 2021-02-28 | 31.30% 10-Q · filed 2021-03-31 | ||||
| 2020-11-30 | 31.30% 10-Q · filed 2020-12-29 | ||||
| 2020-08-31 | 29.40% 10-Q · filed 2020-09-30 | ||||
| 2020-05-31 | 29.40% 10-K · filed 2022-07-27 | ||||
| 2020-02-29 | 29.40% 10-Q · filed 2020-04-03 | ||||
| 2019-11-30 | 29.40% 10-Q · filed 2019-12-27 | ||||
| 2019-08-31 | 27.00% 10-Q · filed 2019-09-26 | ||||
| 2019-05-31 | 27.00% 10-K · filed 2021-07-30 | ||||
| 2018-05-31 | 27.70% 10-K · filed 2020-07-30 | ||||
| 2017-05-31 | 27.70% 10-K · filed 2019-07-30 | 35.20% 10-K · filed 2017-07-28 | |||
| 2016-05-31 | 33.30% 10-Q · filed 2017-03-31 | ||||
| 2015-05-31 | 36.20% 10-K · filed 2017-07-28 | ||||
| 2015-02-28 | 36.20% 10-Q · filed 2015-04-01 | ||||
| 2014-11-30 | 36.20% 10-Q · filed 2014-12-30 | ||||
| 2014-05-31 | 33.10% 10-K · filed 2016-07-29 | ||||
| 2014-02-28 | 33.10% 10-Q · filed 2014-04-04 | ||||
| 2013-11-30 | 33.10% 10-Q · filed 2014-01-09 | ||||
| 2013-08-31 | 33.10% 10-Q · filed 2013-09-30 | ||||
| 2013-05-31 | 39.20% 10-K · filed 2015-07-30 | ||||
| 2013-02-28 | 39.20% 10-Q · filed 2013-03-28 | ||||
| 2012-11-30 | 39.20% 10-Q · filed 2012-12-28 | ||||
| 2012-05-31 | 36.40% 10-K · filed 2014-07-30 | ||||
| 2011-05-31 | 35.80% 10-K · filed 2013-07-30 | 38.80% 10-Q · filed 2011-09-30 | |||
| 2010-05-31 | 37.80% 10-K · filed 2012-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |